forum

CADILAHC Share Price Discussion

Cadila Healthcare Ltd.
Sector: Pharmaceuticals and health care
... Read more
CADILAHC Share Price *
241.2 +2.25 (0.94%)
* (quote may be delayed)

CADILAHC Discussion Forum

Nifty trading in a 350 point range; TVS Motor, ICICI Bank among 5 stocks that can return 8-13%
As Nifty continues trading in a 350 point range, here are five stocks that can return 8-13 percent in near term:
Moneycontrol
Like
reply
Reply
share
Share
SAFE PORTFOLIO in CADILAHC
Momentum buy above 231 sustains for 235-238-240...

Hit 240
Like
reply
Reply
share
Share

CLSA on Cadila Health
Buy, TP Rs 285
Attractive val of 15x FY21CL earnings
Believe expectations on earnings & monetization of innovation portfolio are quite modest, & even a small positive surprise can drive a PE re-rating
Like
reply
Reply
share
Share

CADILAHC - chart - 340639
CADILA SELL 232-233
Like
reply
Reply
share
Share

Momentum buy above 231 sustains for 235-238-240
SL-228. Enter only sustains levels.
Disclaimer-educational purpose only.
Like
reply
Reply
share
Share

★2👉🏻 *Cadila*
Buy Above 231.65
SL 229.50
TGT 234.85
Like
reply
Reply
share
Share
Explainer: How Indian pharma companies are riding the biosimilars wave
A Morgan Stanley report says that as many as nine biologic drugs have either gone off patent or will do so by 2025, with combined revenues of $62 billion in 2018.
Moneycontrol
Like
reply
Reply
share
Share

Buy Cadillac trading at 211, it will move up only from here
Like
reply
Reply (3)
share
Share
Latest replies

213.80

215.35

218
Umang Thakur in CADILAHC
Buy cadilahc above 216 Sl 213 Target 218/221/225

Made high of 217.30 but because of weak market started falling most probably will hit sl..
Like
reply
Reply
share
Share
Top 15 stocks in which foreign investors raised stakes in June qtr; do you own any?
Lately, however, FPIs have been on a selling spree withdrawing around 25,000 crore from cash market since the budget on July 5. DIIs, on the other hand, buying shares worth over Rs 30,000 crore.
Moneycontrol
Like
reply
Reply
share
Share

Buy cadilahc above 216
Sl 213
Target 218/221/225
Like
reply
Reply
share
Share
Hold Cadila Healthcare; target of Rs 275: Sharekhan
Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 275 in its research report dated August 09, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Buy Cadila Healthcare; target of Rs 265: HDFC Securities
HDFC Securities is bullish on Cadila Healthcare has recommended buy rating on the stock with a target price of Rs 265 in its research report dated August 10, 2019.
www.moneycontrol.com
Like
reply
Reply
share
Share
Hold Cadila Healthcare; target of Rs 250: ICICI Direct
ICICI Direct recommended hold rating on Cadila Healthcare with a target price of Rs 250 in its research report dated August 12, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Buy Cadila Health; target of Rs 275: Motilal Oswal
Motilal Oswal is bullish on Cadila Health has recommended buy rating on the stock with a target price of Rs 275 in its research report dated August 10, 2019.
www.moneycontrol.com
Like
reply
Reply
share
Share
Hold Cadila Healthcare; target of Rs 275: Sharekhan
Sharekhan recommended Hold rating on Cadila Healthcare with a target price of Rs 275 in its research report dated August 09, 2019.
moneycontrol.com
Like
reply
Reply
share
Share
Cadila Health Consolidated June 2019 Net Sales at Rs 3,496.30 crore, up 20.82% Y-o-Y
moneycontrol.com
Like
reply
Reply
share
Share
Cadila Health Standalone June 2019 Net Sales at Rs 1,343.80 crore, down 10.71% Y-o-Y
moneycontrol.com
Like
reply
Reply
share
Share

CADILA 260 CALL CMP 1.50 SL 0 TGT HERO
Like
reply
Reply
share
Share

RESULT TODAY CADILA FUTURE LONG CMP 233 SL 219 TGT 265
Like
reply
Reply
share
Share

**CASH CALL**
**********************
**SHORT:** CADILAHC @ 224.60
**STOP LOSS:** YOURS
**TARGET:** 221.45
Like
reply
Reply (1)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Aug 6 8:35 PM

NO MOVEMENT
EXIT

Hold till market correction
Like
reply
Reply
share
Share

CADILAHC - chart - 296021
Cadila
Like
reply
Reply
share
Share
Top buy and sell ideas by Sudarshan Sukhani, Mitessh Thakkar, Prakash Gaba for short term
Sudarshan Sukhani of s2analytics.com recommends buying Mindtree with stop loss of Rs 702 and target of Rs 725 and Pidilite Industries with stop loss at Rs 1215 and target of Rs 1255.
moneycontrol.com
Like
reply
Reply
share
Share

Buy cadilahc cmp...233.... sl...231.... tgt..240
Like
reply
Reply (1)
share
Share
Latest replies
Gopan @gopan
Jul 29 4:17 PM

Sl..taken
Stocks in the news: ICICI Bank, Cadila Health, Mahindra Life, Vedanta, Uflex, Granules, NHPC
Maruti Suzuki | Allahabad Bank | Future Lifestyle Fashions | ICICI Bank | Power Mech Projects | Manpasand Beverages and Usha Martin are stocks which are in news today.
www.moneycontrol.com
Like
reply
Reply
share
Share
Stocks in the news: ICICI Bank, Cadila Health, Mahindra Life, Vedanta, Uflex, Granules India
Maruti Suzuki | Allahabad Bank | Future Lifestyle Fashions | ICICI Bank | Power Mech Projects | Manpasand Beverages and Usha Martin are stocks which are in news today.
www.moneycontrol.com
Like
reply
Reply
share
Share
‘How low can a stock go?’ is the wrong question to ask; focus on these 4 fundamental factors instead
Empirical evidence suggests very few stocks make it to earlier levels post a significant correction. Even if the stock bottoms out, recovery to a previous high has been rare, which is the main reason for buying the stock after a sharp correction in the first place
moneycontrol.com
Like
reply
Reply
share
Share
Cadila’s Ankleshwar facility completes USFDA inspection with no observations
The United States Food and Drug Administration (USFDA) inspected the company’s active pharmaceutical ingredient manufacturing facility located at Ankleshwar from July 22-26, 2019, Cadila Healthcare said in a filing to BSE.
moneycontrol.com
Like
reply
Reply
share
Share

CADILAHELT
CADILAHC - chart - 287310
Like
reply
Reply
share
Share

Short Term Cash:
We recommend you to Buy CADILAHC @ 232.50-234.50 SL 224.80 TGT 251.00
Like
reply
Reply
share
Share

Cadila appears to be in recovery mode.
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share

Buy Cadilahc Fut 234-234.50 SL 230 Target 235.50-240
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
Yogananda N Naidu in CADILAHC
BUY CADILA ABOVE ⬆️ 224 TGS 226 » 228 » 230 SL 220

CADILA 228 WITH +7200 ✅✅
Like
reply
Reply
share
Share
Yogananda N Naidu in CADILAHC
BUY CADILA ABOVE ⬆️ 224 TGS 226 » 228 » 230 SL 220

CADILA 226 WITH +3600 ✅
Like
reply
Reply
share
Share

**CASH CALL**
**********************
**BUY:** CADILAHC -226.00
**STOP LOSS:** YOURS
**TARGET:** 228.50
Like
reply
Reply (8)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Jul 9 4:33 PM

227.55
INTRADAY Options @teamIOFno
Jul 9 5:02 PM

228.30
INTRADAY Options @teamIOFno
Jul 9 5:05 PM

228.50
INTRADAY Options @teamIOFno
Jul 9 5:05 PM

228.85
INTRADAY Options @teamIOFno
Jul 9 5:06 PM

**TARGET REACHED**

BUY CADILA ABOVE ⬆️ 224 TGS 226 » 228 » 230 SL 220
Like
reply
Reply
share
Share

POSITIONAL SHORT CADILAHC 25JUL2019 FUTURES @ 223.4
TGT : 208-199-189-178
SL : 230
Like
reply
Reply
share
Share
Like
reply
Reply
share
Share
INTRADAY TADKA in CADILAHC
FUTURE LOVER #CADILAHC FUT SELL BELOW 232.25 TGT OPEN

#CADILAHC FUT MADE LOW 229.70
(3600 PROFIT)
Like
reply
Reply
share
Share
INTRADAY TADKA in CADILAHC
FUTURE LOVER #CADILAHC FUT SELL BELOW 232.25 TGT OPEN

#CADILAHC FUT KEEP SL 234 ABOVE
Like
reply
Reply
share
Share

FUTURE LOVER
#CADILAHC FUT SELL BELOW 232.25 TGT OPEN
Like
reply
Reply
share
Share

**CASH CALL**
**********************
**BUY:** CADILAHC @ 236.75
**STOP LOSS:** YOURS
**TARGET:** 3 POINTS
Like
reply
Reply (1)
share
Share
Latest replies
INTRADAY Options @teamIOFno
Jul 4 8:37 PM

237.60

Long term blue cheap comp
Like
reply
Reply
share
Share

Buy Cadila
SL-239 TGT -246/253
Like
reply
Reply
share
Share
  • CADILAHC - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization35,491.84
    Enterprise Value38,320.54
    Price to Earnings35.57
    Price to Book Value3.96
    Return on Capital Employed0.15
    Return on Equity0.14
    Face Value1
    Dividend Yield0.01
  • CADILAHC Share Price - Technicals

    keyboard_arrow_down
    CADILAHC - 52 Week High₹420
    CADILAHC - 52 Week Low₹206.5
  • CADILAHC - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    13-Aug-19Nirmal BangBuy315
    13-Aug-19Karvy Stock BrokingHold261
    10-Aug-19HDFC SecuritiesBuy265
    9-Aug-19SharekhanHold275
    9-Aug-19Prabhudas LilladherAccumulate266
    View all CADILAHC - Share Targets - Broker Reports
  • CADILAHC Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Sep 18240242.3236.05241.25
    Sep 17242243.35237.1238.95
    Sep 16240.1248239.55242.3
    Sep 13240242.75235.65241.9
    Sep 12241.5243.8236.9239.35
  • CADILAHC Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹229.37
    30 Day Moving Average₹227.65
    50 Day Moving Average₹229.26
    100 Day Moving Average₹245.73
    200 Day Moving Average₹291.52
  • CADILAHC - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue5,8093,230.70.8
    Operating Profit1,646321.14.13
    Profit Before Tax1,497642.21.33
    Net Income1,090661.90.65
  • CADILAHC - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds8,9567,7450.16
    Total Liabilities4,5364,4840.01
    Total Assets13,49212,2300.1
  • CADILAHC - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity2891,291.9-0.78
    Cash from Investing Activity26-2,904.5-1.01
    Cash from Financing Activity-1481,365.6-1.11
    Net Cash Flow167-247-1.68
  • CADILAHC - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.090.06
    Return on Equity0.140.1
    Return on Capital Employed0.150.07
  • CADILAHC - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit0.07
    3 Year CAGR Growth in EBIDTA0.08
    3 Year CAGR Growth in Net Income-0.14
    3 Yr CAGR Growth - Diluted EPS-0.83
  • CADILAHC - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.65
    5 Year CAGR Growth in Operating Profit1.33
    5 Year CAGR Growth in EBIDTA1.44
    5 Year CAGR Growth in Net Income1.19
    3 Yr CAGR Growth - Diluted EPS-0.56
  • CADILAHC Share Price - Recent News

    keyboard_arrow_down
    NewsBot
    Sep 10 3:38 PM
    Nifty trading in a 350 point range; TVS Motor, ICICI Bank among 5 stocks that can return 8-13%
    Moneycontrol
    NewsBot
    Aug 28 2:08 AM
    Explainer: How Indian pharma companies are riding the biosimilars wave
    Moneycontrol
    NewsBot
    Aug 22 7:33 PM
    Top 15 stocks in which foreign investors raised stakes in June qtr; do you own any?
    Moneycontrol
    NewsBot
    Aug 14 9:08 PM
    Hold Cadila Healthcare; target of Rs 275: Sharekhan
    moneycontrol.com
    NewsBot
    Aug 14 7:13 PM
    Buy Cadila Healthcare; target of Rs 265: HDFC Securities
    www.moneycontrol.com
    NewsBot
    Aug 13 8:58 PM
    Hold Cadila Healthcare; target of Rs 250: ICICI Direct
    moneycontrol.com
    NewsBot
    Aug 12 6:38 PM
    Buy Cadila Health; target of Rs 275: Motilal Oswal
    www.moneycontrol.com
    NewsBot
    Aug 12 6:38 PM
    Hold Cadila Healthcare; target of Rs 275: Sharekhan
    moneycontrol.com
    NewsBot
    Aug 10 12:28 AM
    Cadila Health Consolidated June 2019 Net Sales at Rs 3,496.30 crore, up 20.82% Y-o-Y
    moneycontrol.com
    NewsBot
    Aug 10 12:28 AM
    Cadila Health Standalone June 2019 Net Sales at Rs 1,343.80 crore, down 10.71% Y-o-Y
    moneycontrol.com
  • CADILAHC - Related Communities

    keyboard_arrow_down
    Share and discuss algorithms, strateg...
    Place for new investors to ask questi...
    Help fellow traders de-stress by shar...
    Share and discuss strategies for tax ...
    Want to know more about an upcoming I...
    MCX:MENTHAOIL
    MCX:CPO
    Purpose: Pool and discuss ideas & sug...
    Sector: Index
    Sector: Finance
  • CADILAHC - More Information

    keyboard_arrow_down

    Cadila HealthcareLtd:
    Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
    Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
    Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
    About Company Information:
    In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
    In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
    In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
    During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
    During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
    On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
    On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
    On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
    On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
    How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
    The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
    Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
    The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
    Cadila HealthcareLtd, Competitors and Sector Peers:
    Aarey Drugs & Pharmaceuticals Ltd. AARDRU
    Aarti Drugs Ltd. AARTDR
    Aayush Food & Herbs Ltd. AAYFOO
    Abbott India Ltd. ABBIND
    ABL Bio-Technologies Ltd. ABLBIO
    Addlife Pharma Ltd. ADDPHA
    Bacil Pharma Ltd. BACPHA
    Bafna Pharmaceuticals Ltd. BAFPHA
    Bajaj Healthcare Ltd. BAJHEA
    Brooks Laboratories Ltd. BROLAB
    Cipla Ltd. CIPLTD
    Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
    Divi's Laboratories Ltd. DIVIL
    Dr. Reddy's Laboratories Ltd. DR
    Dujohn Laboratories Ltd. DUJLAB
    Earum Pharmaceuticals Ltd.
    Elder Health Care Ltd. ELDHEA
    Elder Pharmaceuticals Ltd. ELDPHA
    Elegant Pharmaceuticals Ltd. ELEPHA
    Gennex Laboratories Ltd. GENLAB
    Genomics Biotech Ltd. GENBIO
    GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
    Glenmark Pharmaceuticals Ltd. GLEPHL
    IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
    JK Pharmachem Ltd. JKPHAL
    Jubilant Life Sciences Ltd. JUBILO
    Jupiter Bioscience Ltd. JUPIBI
    Lupin Ltd. LUPLTD
    Lyka Labs Ltd. LYKLAB
    Novartis India Ltd. NOVAIN
    Ortin Laboratories Ltd. ORTLAB
    Piramal Enterprises Ltd. NICPIR
    Piramal Phytocare Ltd. PIRLIF
    Ranbaxy Laboratories Ltd. RANLAB
    Sanjivani paranteral Ltd. SANPAR
    Sanofi India Ltd. AVEPHA
    Sarvodaya Labs Ltd. SARLAB
    Sun Pharmaceutical Industries Ltd. SUN28
    TTK Healthcare Ltd. TTKHEA
    Venmax Drugs & Pharmaceuticals Ltd. YENDRU
    Venus Remedies Ltd. VENREM
    Zenith Healthcare Ltd. ZENHEA
    Zenlabs Ethica Ltd. SHRLAK
    Zenotech Laboratories Ltd. ZENLAB
    Zim Laboratories Ltd. ZIMLAB
    Zora Pharma Ltd.[Amalgamated] ZORPHA
    Zota Healthcare Ltd. ZOTHEA
    Zyden Gentec Ltd. ZYDGEN
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.